NVAX vs. BCRX, KOD, CRSP, HALO, EXEL, SANA, DNA, FUSN, CGON, and BEAM
Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include BioCryst Pharmaceuticals (BCRX), Kodiak Sciences (KOD), CRISPR Therapeutics (CRSP), Halozyme Therapeutics (HALO), Exelixis (EXEL), Sana Biotechnology (SANA), Ginkgo Bioworks (DNA), Fusion Pharmaceuticals (FUSN), CG Oncology (CGON), and Beam Therapeutics (BEAM). These companies are all part of the "biological products, except diagnostic" industry.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
In the previous week, Novavax had 24 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 40 mentions for Novavax and 16 mentions for BioCryst Pharmaceuticals. Novavax's average media sentiment score of 1.11 beat BioCryst Pharmaceuticals' score of 0.52 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.
BioCryst Pharmaceuticals currently has a consensus price target of $14.00, indicating a potential upside of 122.93%. Novavax has a consensus price target of $14.00, indicating a potential upside of 7.61%. Given Novavax's stronger consensus rating and higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Novavax.
Novavax received 365 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 74.12% of users gave Novavax an outperform vote while only 66.43% of users gave BioCryst Pharmaceuticals an outperform vote.
BioCryst Pharmaceuticals has higher earnings, but lower revenue than Novavax. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 4.4% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
BioCryst Pharmaceuticals has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
Novavax has a net margin of -40.01% compared to Novavax's net margin of -58.69%.
Summary
BioCryst Pharmaceuticals beats Novavax on 10 of the 17 factors compared between the two stocks.
Get Novavax News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
